Introduction
============

The burden of infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) is increasing among different patient populations globally [@b1]--[@b3]. Following its initial report in 1961 [@b4], MRSA has remained an important cause of infections in healthcare facilities and in the community globally [@b1]--[@b3]. Although previously restricted to healthcare facilities, especially large tertiary-care facilities [@b5], MRSA has been increasingly identified as a major cause of community-associated infections in previously healthy hosts since the late 1990s [@b6]--[@b8]. These new MRSA strains have been described as community-acquired or community-originated MRSA. Community-acquired MRSA can be distinguished from healthcare-associated MRSA isolates on the basis of patient risk factors such as history of previous hospitalization, previous antibiotic treatment, admission to intensive care units, advanced age, location at the time of infection and genetic characteristics [@b6],[@b7].

Advances in molecular typing techniques, including pulsed-field gel electrophoresis (PFGE) [@b9], staphylococcal cassette chromosome mec (SCC*mec*) [@b10], Spa typing [@b11],[@b12] and multilocus sequence typing (MLST) [@b13] have facilitated the study of clonal distributions of MRSA strains isolated in different countries and revealed a diversity in the genetic backgrounds of MRSA isolated in different geographical locations [@b14]. In addition to the capacity to acquire antibiotic-resistance determinants, some MRSA strains have also acquired the ability to spread rapidly between patients within and between hospitals, thereby causing major problems for infection control. Hence, some epidemic MRSA strains have spread internationally [@b14]. For example, the epidemic MRSA clones ST239-MRSA-III, ST22-MRSA-IV and ST30-MRSA-IV are widely distributed globally [@b8] whereas the USA300 MRSA is the dominant MRSA clone in North America and another MRSA clone, the ST80-MRSA-IV clone, is distributed widely in European countries, North Africa, the Middle East and the Gulf Cooperation Council (GCC) countries [@b15].

Studies on the distribution of MRSA clones in the GCC countries are limited [@b15]--[@b18]. Although MRSA has been reported in the Sultanate of Oman since 1995 [@b19], there are no data on the MRSA genotypes prevalent in the country. This study was conducted to determine the prevalence and distribution of MRSA clones in a tertiary hospital in the Sultanate of Oman.

Materials and Methods
=====================

Setting
-------

The Sultan Qaboos University Hospital (SQUH) is a 550-bed teaching hospital of the Sultan Qaboos University. The hospital has 13 different medical departments, which include Surgery, Oral Health, Ophthalmology, Obstetrics & Gynaecology, Medicine, Human Clinical Anatomy, Haematology, Genetics, Family Medicine and Public Health, Emergency Medicine, Child Health, Behavioural Medicine, Anaesthesia and Intensive Care in addition to technical departments.

MRSA isolates
-------------

A total of 79 non-repeat MRSA isolates obtained from clinical samples between March and December 2011 at the SQUH were investigated. Isolation and identification of MRSA from clinical samples were performed in the diagnostic microbiology laboratory of SQUH based on cultural characteristics, Gram stain, positive tube coagulase and DNAse tests. Methicillin resistance was confirmed by the amplification of *mecA* as described previously [@b20]. The isolates were obtained from samples listed in Table[1](#tbl1){ref-type="table"}. Pure cultures of the isolates were preserved in Cryo-bank vials at −80°C. Molecular typing was performed at the Department of Microbiology, Health Science Centre, Kuwait University, Kuwait.

###### 

Association of Panton--Valentine leucocidin-positive (PVL+) methicillin-resistant *Staphylococcus aureus* isolates with different types of infections

  Types of infection                              No. of strains   No. (%) of PVL+
  ----------------------------------------------- ---------------- -----------------
  Skin and soft tissue infections                 29               21 (72.4)
  Abscess                                         19               14 (73.7)
  Ulcer[a](#tf1-1){ref-type="table-fn"}           4                2 (50)
  Skin lesions/boils/furuncles                    3                3 (100)
  Folliculitis                                    1                1 (100)
  Cellulitis                                      1                0 (0.0)
  Blisters                                        1                1 (100)
  Wounds                                          22               9 (40.9)
  Postsurgical                                    11               3 (27.3)
  Trauma                                          11               6 (54.5)
  Respiratory tract infections                    11               0
  Pneumonia                                       4                0 (0.0)
  Others[b](#tf1-2){ref-type="table-fn"}          7                0 (0.0)
  Septicaemia/bacteraemia                         6                3 (50)
  Ear infection                                   5                1 (20)
  Invasive infections (osteomyelitis/arthritis)   2                1 (50)
  Colonization[c](#tf1-3){ref-type="table-fn"}    4                0 (0.0)
  Total                                           79               35 (44.3)

Bed Sore, pressure sore, mouth and groin ulcers and diabetic foot ulcer.

Including cystic fibrosis.

Nasal and umbilical.

Antibacterial susceptibility testing
------------------------------------

Antibacterial susceptibility testing was performed by the disc diffusion method [@b21] with the following antimicrobial disks (Oxoid, Basingstoke, UK): benzyl penicillin (2 U), cefoxitin (30 μg), kanamycin (30 μg), mupirocin (200 μg and 5 μg), gentamicin (10 μg), erythromycin (15 μg), clindamycin (2 μg), chloramphenicol (30 μg), tetracycline (10 μg), trimethoprim (2.5 μg), fusidic acid (10 μg), rifampicin (5 μg), ciprofloxacin (5 μg), teicoplanin (30 μg), vancomycin (30 μg) and linezolid (30 μg). Discs containing cadmium acetate (50 μg), propamidine isethionate (100 μg) and mercuric chloride (109 μg) were prepared in the laboratory. Minimum inhibitory concentration (MIC) for cefoxitin, vancomycin and teicoplanin were determined with E-test strips (AB BioMérieux, Marcy l\'Etoile, France) according to the manufacturer\'s instructions. *Staphylococcus aureus* strain ATCC25923 was used as a quality control strain for susceptibility testing.

SCC*mec typing*
---------------

SCC*mec* typing was performed by PCR assays as described previously [@b22],[@b23].

Detection of genes for Panton--Valentine leucocidin
---------------------------------------------------

All isolates were tested for the presence of *lukS-PV-lukF-PV*, which codes for Panton--Valentine leucocidin (PVL), in PCR assays using previously described primers and protocols [@b24],[@b25]. PCR products were analysed by agarose gel electrophoresis.

Pulsed-field gel electrophoresis
--------------------------------

The PFGE of *Sma*I-digested chromosomal DNA was performed as described previously [@b26]. PFGE patterns were compared using B[ioinformatics]{.smallcaps} FPQ[uest]{.smallcaps} software version 4.0 software (BioRad, Hercules, CA, USA) and Dice correlation coefficients, with optimization and band position tolerance set at 1.0% and 2.3%, respectively [@b27].

Spa typing
----------

Spa typing was performed as described by Harmsen *et al*. [@b12] for all MRSA isolates. DNA sequencing was performed using a 3130×1 genetic analyser (Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer\'s protocol. Isolates were assigned to particular Spa types using the Spa typing website (<http://www.spaserver.ridom.de>).

Multilocus sequence typing
--------------------------

The MLST was performed on all isolates as described by Enright *et al*. [@b13]. Isolates were assigned a sequence type (ST) according to the MLST website (<http://www.mlst.net>).

Results
=======

The 79 MRSA isolates were obtained from 46 male patients and 33 female patients. Forty-three patients were 19--59 years old, 26 patients were ≤18 years old and ten patients were ≥60 years.

Thirty-five (44.3%) MRSA isolates were positive for the presence of *lukS-PV-lukF-PV*, mostly in isolates that were associated with skin and soft tissue infections and septicaemia but not in isolates recovered from colonization or respiratory tract specimens (Table[1](#tbl1){ref-type="table"}).

Antibiotic resistance of MRSA isolates
--------------------------------------

All 79 MRSA isolates were susceptible to vancomycin (MIC ≤ 2 mg/L), teicoplanin (MIC ≤ 2 mg/L), linezolid, tigecycline and mupirocin but were resistant to tetracycline (*n* = 24), erythromycin (*n* = 21), clindamycin (*n* = 19), kanamycin (*n* = 17), trimethoprim (*n* = 15), ciprofloxacin (*n* = 14) and fusidic acid (*n* = 12; 15.2%), gentamicin (*n* = 10) and streptomycin (*n* = 6). One isolate was resistant to chloramphenicol. Sixteen isolates expressed inducible resistance to clindamycin.

All 79 isolates were resistant to mercuric chloride and 68 (86.1%) isolates were resistant to ethidium bromide and cadmium acetate. Nine isolates were resistant to more than three classes of non-β-lactam antibiotics tested and were classified as multiresistant isolates.

Molecular typing of MRSA isolates
---------------------------------

Table[2](#tbl2){ref-type="table"} summarizes the results typing the 79 MRSA isolates using PFGE, SCC*mec*, Spa typing and MLST. The isolates were classified into 19 PFGE patterns ([Fig. 1](#fig01){ref-type="fig"}), four SCC*mec* types, 25 Spa types and 21 sequence types.

###### 

Characteristics of methicillin-resistant *Staphylococcus aureus* from SQUH

  PFGE type   \#                                      Antimicrobial-resistance pattern             SCC*mec*   Spa type   MLST      PVL
  ----------- --------------------------------------- -------------------------------------------- ---------- ---------- --------- ---------
  1           20                                      Cd, Hg, Eb                                   IV         t304       ST6       neg
  1           Hg                                      IV                                           t304       ST6        neg       
  1           Cd, Hg                                  IV                                           t304       ST6        neg       
  1           Cd, Hg, Em, Clin                        IV                                           t304       ST6        neg       
  1           Cd, Hg, Eb, Fd                          IV                                           t304       ST6        neg       
  1           Hg, Em, Clin                            IV                                           t304       ST6        neg       
  3           Hg, Eb                                  IV                                           t304       ST6        neg       
  1           Cd, Hg                                  IV                                           t7966      ST6        neg       
  2           5                                       Cd, Hg, Eb, Tet                              IV         t690       ST1295    pos (4)
  2           Cd, Hg, Eb, Tet, Em, Clin,              IV                                           t690       ST1295     pos (1)   
  3           Cd, Hg, Eb, Tet, Cip                    IV                                           t690       ST1295     pos (3)   
  1           Cd, Hg, Eb                              IV                                           t690       ST1295     pos       
  1           Cd, Hg, Tet, Fd                         IV                                           t690       ST1295     pos       
  3           1                                       Cd, Hg, Eb, Gm, Km, Sm, Tet, Fd              IV         t044       ST80      neg
  1           Cd, Hg, Eb, Km, Sm, Tet, Em, Clin, Fd   IV                                           t044       ST80       pos       
  1           Cd,Hg, Eb, Km, Sm, Tet, Fd              IV                                           t044       ST80       pos       
  1           Cd, Hg, Eb, Tet, Em, Clin               IV                                           t8154      ST450      neg       
  1           Cd, Hg, Eb, Km, Em, Clin                IV                                           t304       ST6        pos       
  1           Cd, Hg, Eb, Km, Sm, Tet, Fd             IV                                           t304       ST6        pos       
  4           4                                       Cd, Hg, Gm, Km, Em, Clin, Tp, Cip            V          t657       ST772     pos
  1           Cd, Hg, Eb, Gm, Km, Em, Clin, Tp, Cip   V                                            t657       ST772      pos       
  1           Cd, Hg, Eb, Gm, Km, Em, Tp              V                                            t2085      ST573      pos       
  5           1                                       Hg, Em, Clin, Tp, Cip,                       IV         t852       ST22      pos
  1           Hg, Eb, Em, Clin, Tp                    IV                                           t852       ST22       pos       
  1           Hg,Gm,Km,Em, Clin, Tp, Cip              IV                                           t852       ST22       pos       
  1           Cd,Hg,Eb, Gm,Km, Tp, Cip                IV                                           t852       ST22       pos       
  6           1                                       Hg, Eb, Fd, Em, Clin                         IV         t002       ST5       pos
  1           Cd, Hg, Eb                              IV                                           t002       ST5        pos       
  1           Hg, Eb, Km, Sm, Em, Clin, Fd            II                                           t003       ST5        neg       
  1           Cd, Hg, Eb, Tet                         IV                                           t855       ST628      pos       
  1           Cd, Hg, Eb, Tet, Tp, Em, Clin, Cip      IV                                           t442       ST487      neg       
  7           1                                       Cd, Hg, Eb                                   IV         t021       ST30      neg
  3           Cd, Hg, Eb                              IV                                           t019       ST30       pos       
  1           Cd, Hg, Eb, Tet, Tp, Fd                 IV                                           t019       ST30       pos       
  8           1                                       Cd, Hg, Tet                                  IV         t5686      ST188     neg
  9           2                                       Cd, Hg, Eb, Km, Sm, Em, Clin, Cip            V          t315       ST361     neg
  10          1                                       Cd, Hg, Eb, Tet, Cm                          V          t688       ST627     neg
  11          1                                       Cd,Hg, Eb                                    IV         t4447      ST631     neg
  12          1                                       Cd, Hg, Eb, Em, Clin, Fd, Tp, Cip            III        t311       ST5       pos
  13          1                                       Cd, Hg, Eb, Em, Clin, Fd                     IV         t127       ST1       neg
  14          1                                       Cd, Hg, Eb, Gm, Km, Em, Clin, Tet, Rf, Cip   III        t632       ST239     neg
  15          1                                       Cd, Hg, Eb, Em, Clin, Tet, Tp, Cip           IV         t064       ST8       neg
  16          1                                       Cd, Hg, Eb, Em, Clin, Fd                     IV         t311       ST1197    pos
  17          1                                       Cd, Hg, Eb, Km, Em, Clin, Cip                IV         t150       ST585     pos
  18          1                                       Cd, Hg, Eb, Tet, Em, Clin                    IV         t8213      ST63      pos
  19          1                                       Hg, Eb, Tp                                   IV         t401       ST1802    neg

Antimicrobials abbreviations:

Cd, cadmium acetete; Clin, clindamycin; Cip, ciprofloxacin; Cm, chloramphenicol; Eb, ethidium bromide; Fd, fusidic acid; Gm, gentaimicn; Hg, mecuric chloride; Km, kanamycin; Rf, rifampicin; Sm, streptomycin; Tet, tetracycline; Tp, trimethoprim; MLST, multilocus sequence typing; PFGE, pulsed-field gel electrophoresis; PVL, Panton -Valentine Leucocidin; SCCmec, staphylococcal chromosome cassette mec.

![Dendrogram of pulsed-field gel electrophoresis patterns of methicillin-resistant *Staphylococcus aureus* isolates obtained from SQUH Oman.](nmi20002-0100-f1){#fig01}

Sixty-eight (86.0%) of the 79 isolates carried the SCC*mec*-IV genetic element while eight isolates (10.1%) carried SCC*mec*-V. Two isolates carried SCC*mec*-III and only one isolate carried SCC*mec*-II. SCC*mec*-I was not detected. A combination of the typing results revealed that ST6-IV/t304 (*n* = 30) was the most common genotype followed by ST1295-IV/t690 (*n* = 12), ST772-V/t657 (*n* = 5), ST22-IV/t852 (*n* = 4), ST30-IV/t019 (*n* = 4), ST80-IV/t044 (*n* = 3), ST5-IV/t002 (*n* = 2) and 15 sporadic genotypes. Based on these results, seven (8.8%) isolates consisting of four ST22-IV/t852, one ST239-III/t632, one ST5-III/t311 and one ST5-II/t003 were recognized healthcare-associated MRSA and 72 (91.2%) isolates that carried SCC*mec*-IV (*n* = 67) or SCC*mec*-V (*n* = 5) genetic elements were community-acquired MRSA.

Discussion
==========

This study has provided initial data on the prevalence and distribution of MRSA genotypes in the SQUH, a major tertiary hospital in the Sultanate of Oman. The MRSA isolates belonged to diverse genetic backgrounds with ST6-IV/t304 clone, detected in 39.2% of the isolates, as the dominant clone. The dominance of the ST6-IV/t304 clone at the SQUH in Oman was different from the situation in Saudi Arabia [@b15] and Qatar [@b18] where ST239-III-MRSA and ST30-IV-MRSA were the dominant MRSA clones, respectively. However, before this report, two ST6-IV/t304 strains were isolated at Tawam Hospital in the United Arab Emirates (UAE) in 2008 [@b16]. Interestingly, 28 of our ST6-IV/t304 isolates lacked genes for PVL and were susceptible to non-β-lactam antibiotics similar to characteristics of the strains from the UAE hospital [@b16]. These observations may indicate the expansion of this clone in the GCC countries.

The other common MRSA clones detected in this study, ST30-IV/t019/t021, ST80-IV/t044, ST772-V/t657, ST5-IV/t002 and ST22-IV/t852 have also been reported previously in other GCC countries [@b15]--[@b18]. However, although ST22-IV-MRSA has been reported previously in Saudi Arabia [@b15], Kuwait [@b7],[@b17], UAE [@b16] and Qatar [@b18], the PVL-positive ST22-IV/t852 clones reported here share similarities with ST22-IV/t852 reported recently in Qatar [@b18] but differ from the ST22-IV/t005 isolated in the UAE [@b16]. Furthermore, three of our four ST22-IV/t852 isolates were multidrug-resistant whereas ST22-IV, reported previously from Kuwait [@b17] and UAE [@b16], were PVL-negative and non-multiresistant. Therefore the ST22-IV/t852 strains may represent an emerging multiresistant variant of ST22-IV MRSA.

The results also showed that only 8.8% of the isolates---belonging to ST239-III, ST5-II, ST5-III and ST22-IV clones---were healthcare-associated MRSA. Therefore, 91.2% of the isolates carrying SCC*mec*-IV/V genetic elements were community-acquired MRSA. These reports highlight differences in the prevalence of MRSA clones in the GCC countries, strengthening the need for national surveillance for the clonal distribution of antibiotic-resistant pathogens in these countries.

The study also revealed that 44.3% of the isolates carried genes for PVL. This was higher than the 14.6% PVL gene-positive MRSA reported recently in a Kuwait hospital [@b28] but lower than the 54.2% positive rate obtained in a Saudi Arabian hospital [@b15], indicating the diversity of MRSA bearing PVL genes in the GCC countries. PVL gene-positive *S. aureus* have been associated with necrotic skin lesions and community-acquired necrotic pneumonia [@b24]. In this study PVL gene-positive MRSA were obtained from skin and soft tissue infections but not from respiratory tract infections. However, the significance of this observation is uncertain because of the small number of MRSA isolated from respiratory tract.

In conclusion, this study has presented the first data on the distribution of MRSA genotypes at the SQUH in Oman. The MRSA isolates belonged to diverse genetic backgrounds with a predominance of CA-MRSA clones comprising ST6-IV/t304 and ST1295-IV/t690, followed by ST772-V/t657, ST30-IV/t019/t021 and ST80-IV/t044.
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